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Submitted Apr 4, 2012; accepted Jul 17, 2012.DISCUSSIONDr Matthew Corriere (Atlanta, Ga). I would like to
congratulate Dr Hamza Rana and his colleagues at Wake Forest
on an excellent presentation and thank them for forwarding
their manuscript to me in advance of the meeting. This work
is a collaboration between vascular surgery and vascular medi-
cine specialists and underscores the vital importance of risk
factor modiﬁcation and vigilant medical management of
patients with lower extremity peripheral arterial disease. In
a cohort of more than 500 young patients (deﬁned as <55
years of age) with premature lower extremity atherosclerosis,
they observed a 19% mortality rate during mean follow-up of
5.6 years. Two thirds of the observed mortalities were attribut-
able to cardiovascular causes, and predictors of overall mortality
included age, coronary disease, cerebrovascular disease, prior
amputation, cancer, and absence of aspirin therapy. The anal-
ysis is impressive in terms of cohort size and diversity, duration
of follow-up, and ﬁndings.
I have four questions:
1. Within the manuscript, you referenced 3- to 5-year mortality
rates of 17% to 32% in patients with premature lower extremity
atherosclerosis from previously published reports that are now
over thirty years old. When comparing those results with
your more current update, it seems that we have made little
or no impact on the mortality rates in this patient population
over a fairly long interval of time that has included some drastic
changes in approaches to cardiovascular risk reduction. Can
you comment on trends in the incidence of premature lower
extremity atherosclerosis over this same time frame, andwhether our current efforts should be focused on primary
versus secondary and tertiary prevention?
2. Your results demonstrate that, save for aspirin use, none of the
mortality risk factors you identiﬁed are modiﬁable. This leaves
the vascular surgeon or vascular medicine practitioner with
little guidance on how to change the care of these complex
patients to impact such a high mortality rate. Given this consid-
eration, did you consider evaluating more detailed surrogate
measures of medical management, such as blood pressure, lipid
or hemoglobin A1C levels, to see where greater focus is
needed?
3. You correctly identify your cohort of patients with premature
lower extremity atherosclerosis as one of the largest and most
diverse, in terms of gender and race/ethnicity, studied to date.
Given the rapidly growing body of evidence supporting signiﬁ-
cant gender- and race-speciﬁc risk proﬁles in patients with periph-
eral arterial disease, can you provide any additional details
regarding gender- and race-speciﬁc mortality? I would be partic-
ularly interested in the race and ethnicity makeup of the
nonwhite subgroup of patients, which accounted for 20% of
your cohort; what proportion of these patients were of African
American race or Hispanic/Latino ethnicity; and how their
mortality compared with white patients.
4. I was particularly impressed that 72% of your patient cohort were
smokers at baseline, suggesting that this is a very important risk
factor for development of premature lower extremity atheroscle-
rosis. Did you evaluate the incidence of smoking cessation over
the study period and whether this impactedmortality during the
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smoking cessation in Winston-Salem, North Carolina?
I would like to thank the SAVS for allowing me to discuss this
important manuscript and again congratulate the authors on their
outstanding work.
Dr Hamza Rana. Thank you so much, Dr Corriere, for your
excellent questions and discussion. I will answer your second ques-
tion ﬁrst, which is regarding the risk factors. All of the available
predictors in our analysis that were included were collected at
the time of the initial evaluation of vascular care, so we did not
look at the intensity of their control or the duration of their risk
factors in this analysis. I completely agree with you that each of
these traditional risk factors has a continuous dose-dependent
effect on the cardiovascular risk, factors that we did not have avail-
able in our study, such as blood pressure control, lipid level, and
blood glucose control. Thus it is one of the limitations of our
study. The second factor that could have contributed to this
ﬁnding is that we looked at all-cause mortality, not the cardiovas-
cular mortality speciﬁcally, but we do plan to look at it in the near
future and report it as a separate analysis. In response to your ﬁrst
question regarding the incidence and prevention strategies, there
are no data from the large population-based studies on the inci-
dence of premature lower extremity atherosclerosis. However,
previous small studies have reported the incidence anywhere
between 2% and 5%, or up to 7% in some studies. In our anecdotal
experience at Wake Forest, we are seeing an increasing number of
patients with premature lower extremity atherosclerosis every year.
With the growing awareness of PAD, I believe that we will see
more and more patients with premature lower extremity athero-
sclerosis. In response to the prevention strategies, I believe all
forms of the prevention strategies are essential, but we should
focus on the primary prevention because it is important. As we
see from the study, premature lower extremity atherosclerosis
has such a high mortality (9- to 10-fold higher than the expected
mortality for the same age), and the majority of these patients
interestingly were on disability at the time of initial evaluation.
Therefore, we need to focus on the primary prevention. Our aimshould be to identify these at-risk populations very early on,
perhaps in their twenties or early thirties, and to initiate and sustain
the treatment more consistently in those populations at risk. In
response to the secondary prevention, I think we need to recog-
nize premature lower extremity atherosclerosis as a coronary artery
disease risk equivalent as these patients remain untreated so that all
of these patients are automatically eligible to get aggressive risk
factor modiﬁcation. There is enormous large evidence base that
can guide us for the prevention strategies. As you saw in our anal-
ysis of aspirin therapy, the patients on aspirin at the time of initial
evaluation had a 55% lower risk of mortality. In response to your
third question about gender and race, for the nonwhite race in
our analysis, almost all of the patients were African Americans.
In our experience, African Americans mostly have infrainguinal
disease, and diabetes was more common in that race. In our multi-
variable model, race and gender were not independent predictors
of mortality. We had 111 patients as nonwhite. There were 26
deaths during the follow-up period, which is close to 24%. In
response to your last question about smoking cessation, as you
have pointed out, 72% of the patients are current smokers;
however, in the data that was not reported here, the patients
who ever smoked were 96% or 97%, so we could assume that we
have made some contribution there as far as the smoking cessation
was concerned. Again, we just looked at predictors at initial evalu-
ation, so we did not look at any intervention. Thus, I do not have
the data on smoking cessation in terms of how it relates as
a predictor of mortality. In terms of what we do in Winston-Salem
for smoking cessation, we do address the smoking cessation at each
visit and we follow the clinical guideline by the United States
Public Health Services which is the 5 A’s: Ask if they smoke, which
mostly is yes; Advise to quit smoking; Assess for readiness; Assist
with a plan that is behavioral therapy where we encourage them
to quit smoking, nicotine replacement therapies, and pharmaco-
logical therapies as well; and Arrange for follow-up, where we try
to discuss smoking cessation at each follow-up visit. We do have
available to us at Wake Forest a smoking cessation clinic, which
is run by the family practitioners whom we utilize.
